Literature DB >> 1555253

Highly concentrated urine-purified Tac peptide fails to inhibit IL-2-dependent cell proliferation in vitro.

G Pizzolo1, C Vincenzi, F Vinante, A Rigo, D Veneri, M Chilosi, S Dusi, G Poli, R Zambello, G Semenzato.   

Abstract

Tac peptide, i.e., the p55 chain of the human interleukin-2 receptor (IL-2R) complex, is detectable as a soluble from (sIL-2R) in normal sera and, at increased levels, in patients with different diseases. Since several immunological abnormalities are observed in most conditions associated with an increase in sIL-2R levels, a down-regulatory effect on IL-2-dependent functions has been postulated as a consequence of binding and functional block of IL-2 by the excess of sIL-2R. To test this hypothesis, we purified sIL-2R from the urine of a patient with hairy cell leukemia and investigated the possible inhibitory effect of this peptide on the in vitro IL-2-induced cell proliferation. The urine-purified molecule was detectable by the specific immunoassay utilized to measure the serum Tac peptide and was constructed by a single polypeptide of about 50 kDa which was able to bind IL-2. Experiments performed with the IL-2-dependent murine CTLL-2 cell line and with PHA-stimulated human peripheral blood mononuclear cells showed that the purified sIL-2R at concentrations up to about 300 nM was unable to block IL-2-dependent cell proliferation. According to these data, which can be explained by the low affinity for IL-2 of the p55 IL-2R chain, it seems unlikely that in vivo the soluble Tac peptide can exert a down regulatory effect on IL-2-induced phenomena through a functional block of IL-2.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1555253     DOI: 10.1016/0008-8749(92)90144-e

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  5 in total

1.  Biological role of the soluble interleukin-2 receptor in sarcoidosis.

Authors:  Remi M M Vanmaris; Ger T Rijkers
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

Review 2.  Lymphocyte and macrophage interleukin receptors in inflammatory bowel disease: a more selective target for therapy?

Authors:  M J Weldon; J D Maxwell
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

3.  Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application.

Authors:  G I Kirchner; A Franzke; J Buer; W Beil; M Probst-Kepper; F Wittke; K Overmann; S Lassmann; R Hoffmann; H Kirchner; A Ganser; J Atzpodien
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

4.  Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer.

Authors:  B Nakata; K H Chung; Y Kato; Y Yamashita; A Inui; Y Arimoto; K Maeda; N Onoda; T Sawada; M Sowa
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

Review 5.  The IL-2 - IL-2 receptor pathway: Key to understanding multiple sclerosis.

Authors:  Daphne Peerlings; Max Mimpen; Jan Damoiseaux
Journal:  J Transl Autoimmun       Date:  2021-09-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.